BioMarin Pharmaceutical’s Revenue Breakdown Worldwide (2016-2022)

BioMarin Pharmaceutical’s Revenue Breakdown Worldwide

(All figures are in millions, except percentages)

Company’s total revenue increased on a yearly as well as a quarterly basis. Earlier, in Q3 2020, the company generated a revenue of $477 million, while in the same quarter of the next year, i.e., Q3 2021, it falls to $408 million showing, a decrease of 15% on a year-on-year basis. When compared on a quarter-on-quarter basis, the revenue witnessed a fall from $500 million in Q2 2021 to $408 million in Q3 2021, making a decline of 18.4%.

BioMarin Pharmaceutical’s revenue can be further bifurcated into the following:

Europe

The revenue generated from this region has seen a lot of movements in the positive, as well as, negative directions. The European region contributes 28% to the total revenue of the company in Q3 2021. Earlier, in Q3 2020, the company generated a total of $121 million from Europe, while in Q2 2021 it rises to $173 million. This shows a 42% rise in revenue from this segment of the company. On a yearly basis, the revenue witnessed a decline of 5%, from $121 million in Q3 2020 to $115 million in Q3 2021. When compared quarterly, the revenue witnessed a fall from $173 million in Q2 2021 to $115 million in Q3 2021, making a decline of 34%.

Latin America

The Latin American region contributes 10% to the total revenue of the company in Q3 2021. Earlier, in Q3 2020, the company generated a total of $44 million from latin America, while in Q2 2021 it falls to $42 million. This shows a 5% fall in revenue from this segment of the company. On a yearly basis, the revenue witnessed a decline of 11.36%, from $44 million in Q3 2020 to $39 million in Q3 2021. When compared quarterly, the revenue witnessed a fall from $42 million in Q2 2021 to $39 million in Q3 2021, making a decline of 8%.

Rest of world

The rest of the world contributes 15% to the total revenue of the company in Q3 2021. Earlier, in Q3 2020, the company generated a total of $59 million, while in Q2 2021 it rises to $83 million. This shows a 40% incline in revenue from this segment of the company. On a yearly basis, the revenue witnessed a slight decline of 1.7%, from $59 million in Q3 2020 to $58 million in Q3 2021. When compared quarterly, the revenue witnessed a fall from $83 million in Q2 2021 to $58 million in Q3 2021, making a decline of 30%.

U.S.

The United States contributes 47% to the total revenue of the company in Q3 2021. Earlier, in Q3 2020, the company generated a total of $253 million from United States, while in Q2 2021 it falls to $202 million. This shows a 20.9% fall in revenue from this segment of the company. On a yearly basis, the revenue witnessed a decline of 22.5%, from $253 million in Q3 2020 to $196 million in Q3 2021. When compared quarterly, the revenue witnessed a fall from $202 million in Q2 2021 to $196 million in Q3 2021, making a decline of 3%.

About BioMarin Pharmaceuticals

BioMarin is a global pharmaceutical company focused on developing first-class and best-in-class therapeutics that provide meaningful 0r relative advances to patients who live with serious and life-threatening or rare genetic diseases. The company remains steady fast to their original mission, which is to bring new treatments to market that will make a big impact on small patient populations. The Company’s patient populations are mostly children or young ones, suffering from diseases that are so rare, that the entire patient population is as few as 1,100 people worldwide. At times, the time is critical with patients having rare diseases, and they strive to quickly develop important or needy therapies for them.